Factors that influence clinical efficacy of live biotherapeutic products
Abstract Traditional probiotics are increasingly being used in a medical context. The use of these products as drugs is considerably different from the traditional use as food or food supplements, as, obviously, the target population is different (diseased versus healthy or at risk population). Besi...
Main Authors: | Bruno Pot, Yvan Vandenplas |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-05-01
|
Series: | European Journal of Medical Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40001-021-00509-7 |
Similar Items
-
Identification of New Potential Biotherapeutics from Human Gut Microbiota-Derived Bacteria
by: Bernardo Cuffaro, et al.
Published: (2021-03-01) -
Comparing technology and regulatory landscape of probiotics as food, dietary supplements and live biotherapeutics
by: Irina Spacova, et al.
Published: (2023-12-01) -
Live Biotherapeutic Products and Probiotics for the Skin
by: Ava M. Vargason, et al.
Published: (2021-12-01) -
Clostridioides difficile infection: microbe-microbe interactions and live biotherapeutics
by: Ruojun Wang
Published: (2023-05-01) -
Co-cultivation is a powerful approach to produce a robust functionally designed synthetic consortium as a live biotherapeutic product (LBP)
by: Fabienne Kurt, et al.
Published: (2023-12-01)